Scientists headed by a team at Tel Aviv University have combined a map of gene regulatory sites with disease-associated loci to uncover a new genetic risk factor for age-related macular degeneration. The work adds new insight into the factors and and mechanisms that may underlie this key cause of visual impairment in adults.
Vijay Pande, PhD, leads a team of about 40 professionals who oversee Andreessen Horowitz's Bio + Health Fund, which the firm describes as being at the cross section of biology and computer science, including applications in computation, machine learning, and AI in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare.
Last month, Thermo Fisher Scientific announced the opening of an 80,000 m2 current good manufacturing practices (cGMP) facility in Hangzhou, China.
In this GEN webinar, sponsored by Charles River, our expert presenters will take us through case studies on CD47, TFR1, and SIRPa antibody discovery programs leveraging the Distributed Bio's antibody discovery technology.
Anima—an mRNA-based drug developer based in Bernardsville, NJ—has granted AbbVie exclusive rights to license and further develop and commercialize the programs following selection of the targets by AbbVie. The companies said their collaboration is designed to combine the biopharma giant’s expertise in cancer and immunology drug development with Anima’s technology platform and expertise in mRNA biology.
In this eBook we present highlights from a process that has been developed – and continues to be refined – with help from nearly two dozen Cytiva scientists. We frame these highlights around common challenges we hear from those who are developing and producing AAV.
Cancer cells’ expression of an immune evasion gene—TANK-binding kinase 1 (TBK1)—may allow the cells to be unaffected by immunotherapy or develop resistance during treatment. In addition, silencing TBK1, or blocking its expressed protein, enhanced cancer cells’ susceptibility to immunotherapy in multiple preclinical models. The results demonstrate that targeting TBK1 is a novel and effective strategy to overcome resistance to cancer immunotherapy.
In a first for a pharmaceutical therapy, human fibroblast derived extracellular vesicles (EVs) loaded with mRNA were successfully used to replace collagen in the deep layers of the skin in an aged animal model. The therapeutic EVs were delivered intradermally using a microneedle array patch that led to improved collagen production in the targeted area for nearly two months. The new mRNA delivery system overcame many limitations associated LNP mediated delivery. It improved safety and increased stability transfection efficiency.
Key trends include fewer and slower financings, a surge of decisive data readouts for cancer vaccines, and further development of mRNA, cell, and gene therapies. Some of these predictions are among the seven biopharma-related trends that GEN has uncovered in its interviews with experts and other industry stakeholders, and in its reviews of reports and public statements. These trends are detailed in this article.
Lonza describes how artificial intelligence, machine learning, and big data are improving safety, quality, and sustainability—all while lowering costs.